Cite
HARVARD Citation
Clark, R. et al. (2019). De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukaemia (DESTINY): a non-randomised, phase 2 trial. Lancet. 6 (7), pp. e375-e383. [Online].